You searched for: ċirrosi (Maltesiska - Engelska)

Ċirrosi
pegasys 360/ 180 or 180 μ g & ribavirin 1000/ 1200 mg 48 weeks (n = 469) svr in pts with vr at wk 12 b (n = 57)

viral load għolja stat ta ’ Ċirrosi
all treatment arms had 24 week treatment-free follow-up.

pazjenti bi fwied ittrapjantat mingħajr ċirrosi
liver transplant patients without cirrhosis

viral load baxxa viral load għolja stat ta ’ Ċirrosi
low viral load= ≤ 800,000 iu/ ml; high viral load= > 800,000 iu/ ml rvr = rapid viral response (hcv rna undetectable) at week 4

m’hemmx tagħrif dwar indeboliment tal-fwied minħabba ċirrosi jew epatite.
no information is available on hepatic impairment due to cirrhosis or hepatitis.

- f’ każijiet severi fejn il- fwied ma jkunx qed jaħdem tajjeb jew ċirrosi mhux ikkumpensata
- severe hepatic dysfunction or decompensated cirrhosis of the liver.

indeboliment sever tal-fwied (klassifikazzjoni child-pugh b jew Ċ) jew ċirrosi mhux ikkumpensata tal-fwied.
severe hepatic impairment (child-pugh classification b or c) or decompensated cirrhosis of the liver.

mhux komuni: Ċirrosi, fibrożi u deġenerazzjoni tal-grass tal-fwied, tnaqqis tal-albumina fis-serum.
uncommon: cirrhosis, fibrosis and fatty degeneration of the liver, decrease in serum albumin.

it-trattament b’micafungin għandu jitwettaq b’analiżi reqqa fuq bażi ta’ riskju/benefiċċju, b’mod partikolari fuq pazjenti li għandhom indeboliment sever fil-funzjoni tal-fwied jew mard kroniku tal-fwied li hu magħruf li jirrapreżenta kondizzjonijiet preneoplastiċi, bħal fibrożi avvanzata fil-fwied , ċirrosi, epatite virali, mard tal-fwied ta’ trabi li għadhom jitwieldu jew difetti konġenitali ta’ l-enzimi, jew li qed jirċievu terapiji konkomitanti li jinkludu karatteristiċi epatotossiċi u/jew ġenotossiċi.
micafungin treatment should be conducted on a careful risk/benefit basis, particularly in patients having severe liver function impairment or chronic liver diseases known to represent preneoplastic conditions, such as advanced liver fibrosis, cirrhosis, viral hepatitis, neonatal liver disease or congenital enzyme defects, or receiving a concomitant therapy including hepatotoxic and/or genotoxic properties.